Mangafodipir trisodium-enhanced magnetic resonance imaging for evaluation of pancreatic mass and mass-like lesions

World Journal of Gastroenterology

Volumn 12, Issue 10, 2006, Pages 1603-1606

  Eser, Gul ^a   Karabacakoglu, Aydin ^a   Karakose, Serdar ^a   Eser, Cengiz ^b   Kayacetin, Ertugrul ^a  

^a SELCUK UNIVERSITY   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

MnDPDP; MRI; Pancreas

Indexed keywords

MANGAFODIPIR; TESLSCAN;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL EXAMINATION; COMMON BILE DUCT CYST; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG INFUSION; FEMALE; GASTRINOMA; HUMAN; HYDATID CYST; LIPOMA; LIVER METASTASIS; LYMPHOMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ADENOCARCINOMA; PANCREAS DISEASE; PANCREAS PSEUDOCYST; PANCREATITIS;

EID: 33645743799     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i10.1603     Document Type: Article

References (16)

1. Romijn MG, Stoker J, van Eijck CH, van Muiswinkel JM, Torres CG, Lameris JS. MRI with mangafodipir trisodium in the detection and staging of pancreatic cancer. J Magn Reson Imaging 2000; 12: 261-268
2. Muller MF, Meyenberger C, Bertschinger P, Schaer R, Marincek B. Pancreatic tumors: evaluation with endoscopic US, CT, and MR imaging. Radiology 1994; 190: 745-751
3. Bluemke DA, Fishman EK, Kuhlman J. CT evaluation following Whipple procedure: potential pitfalls in interpretation. J Comput Assist Tomogr 1992; 16: 704-708
4. Coley SC, Strickland NH, Walker JD, Williamson RC. Spiral CT and the pre-operative assessment of pancreatic adenocarcinoma. Clin Radiol 1997; 52: 24-30
5. Bartolozzi C, Lencioni R, Donati F, Cioni D. Abdominal MR: liver and pancreas. Eur Radiol 1999; 9: 1496-1512
6. Wang C, Johansson L, Western A, Fagertun H, Ahlstrom H. Sequence optimization in mangafodipir trisodium-enhanced liver and pancreas MRI. J Magn Reson Imaging 1999; 9: 280-284
7. Hustvedt SO, Grant D, Southon TE, Zech K. Plasma pharmacokinetics, tissue distribution and excretion of MnDPDP in the rat and dog after intravenous administration. Acta Radiol 1997; 38: 690-699
8. Ahlstrom H, Gehl HB. Overview of MnDPDP as a pancreas-specific contrast agent for MR imaging. Acta Radiol 1997; 38: 660-664
9. Kloppel G, Maillet B. Classification and staging of pancreatic nonendocrine tumors. Radiol Clin North Am 1989; 27:105-119
10. Kalser MH, Barkin J, MacIntyre JM. Pancreatic cancer. Assessment of prognosis by clinical presentation. Cancer 1985; 56: 397-402
11. Warshaw AL, Gu ZY, Wittenberg J, Waltman AC. Preoperative staging and assessment of resectability of pancreatic cancer. Arch Surg 1990; 1Z5: 230-233
12. Vellet AD, Romano W, Bach DB, Passi RB, Taves DH, Munk PL. Adenocarcinoma of the pancreatic ducts: comparative evaluation with CT and MR imaging at 1.5 T. Radiology 1992; 183: 87-95
13. Schima W, Fugger R. Evaluation of focal pancreatic masses: comparison of mangafodipir-enhanced MR imaging and contrast-enhanced helical CT. Eur Radiol 2002; 12: 2998-3008
14. Gehl HB, Vorwerk D, Klose KC, Gunther RW. Pancreatic enhancement after low-dose infusion of Mn-DPDP. Radiology 1991; 180: 337-339
15. Gehl HB, Urhahn R, Bohndorf K, Klever P, Hauptmann S, Lodemann KP, Matern S, Schumpelick V, Gunther RW. MnDPDP in MR imaging of pancreatic adenocarcinoma: initial clinical experience. Radiology 1993; 186: 795-798
16. Ito K, Koike S, Matsunaga N. MR imaging of pancreatic diseases. Eur J Radiol 2001; 38: 78-93